首页> 外文期刊>Translational Oncology >Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
【24h】

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer

机译:鉴定AR / Ar-V7通常靶向的Ar-V7下游基因,并在抗阉割前列腺癌中特别靶向AR-V7

获取原文
           

摘要

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) under androgen deprivation therapy, by mechanisms e.g. expression of androgen receptor (AR) splice variant-7 (AR-V7). Here we conducted comprehensive epigenome and transcriptome analyses comparing LNCaP, primary PC cells, and LNCaP95, AR-V7-expressing CRPC cells derived from LNCaP. Of 399 AR-V7 target regions identified through ChIP-seq analysis, 377 could be commonly targeted by hormone-stimulated AR, and 22 were specifically targeted by AR-V7. Among genes neighboring to these AR-V7 target regions, 78 genes were highly expressed in LNCaP95, while AR-V7 knockdown led to significant repression of these genes and suppression of growth of LNCaP95. Of the 78 AR-V7 target genes, 74 were common AR/AR-V7 target genes and 4 were specific AR-V7 target genes; their most suppressed genes by AR-V7 knockdown wereNUP210andSLC3A2, respectively, and underwent subsequent analyses.NUP210andSLC3A2were significantly upregulated in clinical CRPC tissues, and their knockdown resulted in significant suppression of cellular growth of LNCaP95 through apoptosis and growth arrest. Collectively, AR-V7 contributes to CRPC proliferation by activating both common AR/AR-V7 target and specific AR-V7 target, e.g.NUP210andSLC3A2.
机译:原代前列腺癌(PC)通过机制对雄激素剥夺疗法进行抗阉割PC(CRPC)进行抗阉割PC(CRPC)。雄激素受体(Ar)剪接变体-7(Ar-V7)的表达。在这里,我们进行了衍生自LNCAP的LNCAP,初级PC细胞和LNCAP95,AR-V7表达的CRPC细胞进行全面的表观蛋白酶体和转录组分析。在通过芯片-SEQ分析中鉴定的399AR-V7靶区域,可以通过激素刺激的AR鉴定377,并且22用Ar-V7特异性靶向。在与这些Ar-V7靶区域相邻的基因中,在LNCAP95中高度表达78个基因,而AR-V7敲低导致这些基因的显着抑制和抑制LNCAP95的生长。在78AR-V7靶基因中,74个是常见的Ar / Ar-V7靶基因,4个是特定的Ar-V7靶基因;它们最抑制的基因分别由Ar-V7敲低Werenup210AndslC3a2分别进行,然后在临床CRPC组织中显着上调了随后的analyses.nup210andslc3a2,它们通过凋亡和生长抑制产生了LNCAP95细胞生长的显着抑制。通过激活常见的Ar / Ar-V7靶和特定的Ar-V7靶,例如,AR-V7通过激活常见的Ar / Ar-V7靶和特定的Ar-V7靶来促进CRPC增殖.Nup210AndsLC3A2。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号